Hot Alert: EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), Chevron Corporation (NYSE:CVX), SanDisk Corp. (NASDAQ:SNDK), AEGON N.V. (NYSE:AEG), Akebia Therapeutics, Inc. (NASDAQ:AKBA)

On Aug. 07, EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) announced financial results for the second quarter and six months ended June 30, 2015. The net loss for the six months ended June 30, 2015 was $22.8 million, compared to a net loss of $17.5 million for the six months ended June 30 2014. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) belongs to Healthcare sector. Its weekly performance is -20.62%. On last trading day company shares ended up $5.16. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) distance from 50-day simple moving average (SMA50) is -18.39%.

The Board of Directors of Chevron Corporation (NYSE:CVX) declared a quarterly dividend of one dollar and seven cents ($1.07) per share, payable September 10, 2015, to all holders of common stock as shown on the transfer records of the Corporation at the close of business August 19, 2015. Chevron Corporation (NYSE:CVX) shares moved up 2.56% in last trading session and ended the day at $85.89. CVX Gross Margin is 38.10% and its return on assets is 4.60%. Chevron Corporation (NYSE:CVX) quarterly performance is -19.20%.

SanDisk Corp. (NASDAQ:SNDK) announced that Judy Bruner, executive vice president, administration and chief financial officer, will address the investment community attended the 17th Annual Pacific Crest Global Technology Leadership Forum on Monday, August 10th at 3:00 p.m. MDT. On 10 August, SanDisk Corp. (NASDAQ:SNDK) shares moved up 2.73% and was closed at $61.03. SNDK EPS growth in last 5 year was 18.80%. SanDisk Corp. (NASDAQ:SNDK) year to date (YTD) performance is -36.88%.

AEGON N.V. (NYSE:AEG) has completed the sale of its Canadian life insurance business to Wilton Re following regulatory approval. The agreement to sell Aegon’s Canadian life insurance business to Wilton Re for CAD 600 million (EUR 417 million) was announced on October 16, 2014. The transaction will result in a book loss of CAD 1.2 billion (EUR 0.8 billion), which will be booked in the third quarter of 2015. Aegon has earmarked the proceeds of this transaction for the redemption of the USD 500 million 4.625% senior bond, due December 2015. AEGON N.V. (NYSE:AEG) ended the last trading day at $7.91. Company weekly volatility is calculated as 1.14% and price to cash ratio as 1.16. AEGON N.V. (NYSE:AEG) showed a weekly performance of 2.33%.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares moved up 3.44% in last trading session and ended the day at $9.62. AKBA return on assets is -33.00%. Akebia Therapeutics, Inc. (NASDAQ:AKBA) quarterly performance is 22.08%.

Leave a Reply

Your email address will not be published. Required fields are marked *